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GPRC6A is a Family C G protein-coupled receptor
recently discovered and deorphanized by our group.
This study integrates chemogenomic ligand infer-
ence, homology modeling, compound synthesis,
and pharmacological mechanism-of-action studies
to disclose two noticeable results of methodological
and pharmacological character: (1) chemogenomic
lead identification through the first, to our knowledge,
ligand inference between two different GPCR fami-
lies, Families A and C; and (2) the discovery of the
most selective GPRC6A allosteric antagonists
discovered to date. The unprecedented inference
of pharmacological activity across GPCR families
provides proof-of-concept for in silico approaches
against Family C targets based on Family A
templates, greatly expanding the prospects of
successful drug design and discovery. The antago-
nists were tested against a panel of seven Family A
and C G protein-coupled receptors containing the
chemogenomic binding sequence motif where
some of the identified GPRC6A antagonists showed
some activity. However, three compounds with at
least 3-fold selectivity for GPRC6A were discov-
ered, which present a significant step forward
compared with the previously published GPRC6A
antagonists, calindol and NPS 2143, which both
display 30-fold selectivity for the calcium-sensing
receptor compared to GPRC6A. The antagonists
constitute novel research tools toward investigating
the signaling mechanism of the GPRC6A receptor at
the cellular level and serve as initial ligands for further
optimization of potency and selectivity enabling
future ex vivo/in vivo pharmacological studies.
INTRODUCTION
The Nobel laureate Sir James Black has stated that ‘‘the best
way to find a new drug is to start from an old’’ (Raju, 2000). In
lead identification practice, old ligands may be new to otherChemistry & Biology 18, 1489–149targets. Such inference of ligands between targets (target
hopping) is typically based on the principle that ‘‘similar targets
have similar ligands.’’ This is the strategy of chemogenomics,
an evolving combination of ligand chemoinformatics and protein
target biology that has demonstrated repeated successes in
lead discovery, primarily at G protein-coupled receptors
(GPCRs) (Garland and Gloriam, 2011a; Harris and Stevens,
2006). The novelty and strength of chemogenomics is that target
similarity is defined based on the binding site characteristics able
to form ligand interactions rather than evolutionary patterns or
natural ligand families, which have long been the choice of
bioinformaticians or pharmacologists, respectively. By adopting
this ‘‘ligands’ view to target similarity,’’ patterns of target simi-
larity can be detected, and ligand-binding correlated, where
the classical measures cannot be used even across diverse
receptors recognizing very heterogeneous physiological ligand
types, including peptides, lipids, and small molecules (Gloriam
et al., 2009; Harris and Stevens, 2006).
GPCRs make up one of the largest protein families in humans
(Venter et al., 2001) and are cell-surface receptors that can be
activated by a broad range of ligands (Bockaert and Pin, 1999).
A large proportion of current drugs (27%–45%) exert their effect
via GPCRs, including well-known examples such as morphine
and propranolol, but the majority of the receptors in this protein
superfamily are as yet untapped for potential therapies (Drews,
2000; Hopkins and Groom, 2002; Overington et al., 2006). Che-
mogenomic techniques have unique capabilities and advan-
tages in the analysis of GPCRs. First, they are not dependent
on target structural data. The significance of this relates to the
fact that there are more than 400 human nonolfactory GPCRs
distributed over five families (Fredriksson et al., 2003), while
crystal structures are limited to six receptors (Cherezov et al.,
2007; Chien et al., 2010; Jaakola et al., 2008; Palczewski et al.,
2000; Warne et al., 2008; Wu et al., 2010) and one family (Family
A/Rhodopsin family). Second, chemogenomic approaches can
identify similarities between targets that are very distantly or
not related using classical classifications based on evolutionary
relationships. Whereas GPCRs are believed to be structurally
conserved, all consisting of a bundle of seven transmembrane
(TM) protein helices (TMHs), the sequence identities between
members of different families is extremely low as a result of
a huge evolutionary gap; the GPCR families separated already
before the split of the nematodes from the chordate lineages
(Fredriksson and Schio¨th, 2005). Finally, chemogenomic
methods can provide receptor activity relationships also for8, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1489
Table 1. The 2-Phenyl-Indole Moieties Paired with Binding Sequence Motifs
Moiety Indole NH Phenyl Whole Structure
Interaction Aromatic-Aromatic Hydrogen bond to
backbone
Hydrophobic Charge neutrality
Receptor residue
positions
5.47T760, 6.48 W797,
6.51F800, and 6.52I801
5.46I759 3.33G667, 3.37T671, 4.56V724,
4.57L725, and 5.46I759
3.36F670, 3.37T671, 5.47T760,
6.51F800, and 6.52I801
Allowed amino acids Aromatic: F,W,Y, and H NOT very large (W)
or basic (KR)
Aromatic or hydrophobic:
F,W,Y,H,A,I,L,M, and V
Not charged residues:
D,E,K, and R
No. required matches 2/4 1/1 2/5 5/5
Ligand moieties and interacting receptor residue positions with allowed amino acids are color-coded. The binding sequence motif has been adapted
from previous analyses (Bondensgaard et al., 2004). Residue positions are denoted using Ballesteros-Weinstein indices (Ballesteros and Weinstein,
1995; Garland and Gloriam, 2011b) and with the mouse GPRC6A amino acid in superscript.
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(allosteric) site than the endogenous agonist, and therefore have
a strong applicability in the design of synthetic drugs.
The GPRC6A receptor belongs to a small family of dimeric
GPCRs, Family C/Glutamate family, which includes eight metab-
otropic glutamate receptors (mGluRs), the calcium sensing
receptor (CaR), the g-aminobutyric acid type B receptor (GABAB)
as well as several taste and orphan receptors (Bra¨uner-Osborne
et al., 2007). The Family C receptors have a characteristic large,
extracellular, ligand-binding ‘‘Venus-flytrap’’ domain, a cysteine-
rich region, a 7TM bundle and an intracellular C terminus (Bra¨u-
ner-Osborne et al., 2007). The GPRC6A receptor is physiologi-
cally activated by L-a-amino acids, with a preference for the
naturally occurring basic amino acids L-arginine, L-lysine and
L-ornithine (Kuang et al., 2005; Wellendorph et al., 2005). De-
pending on which signaling pathway is studied, the receptor is
also positively modulated (Christiansen et al., 2007; Kuang
et al., 2005) or directly activated (Pi et al., 2005) by divalent
cations. GPRC6A has a broad expression profile in humans,
mice, and rats (Kuang et al., 2005; Pi et al., 2005; Wellendorph
and Bra¨uner-Osborne, 2004; Wellendorph et al., 2007). The
broad ligand recognition and tissue expression have obscured
the elucidation of the physiological function of the GPRC6A
receptor, however, with the generation of GPRC6A knockout
mice, potential physiological roles have emerged, among these
severe metabolic and endocrinological disturbances (Oury
et al., 2011; Pi et al., 2008; Wellendorph et al., 2009b). However,
large discrepancies have been observed between different
strains of knockout mice (Pi et al., 2008; Wellendorph et al.,
2009b) that underline the strong need for selective pharmacolog-
ical tool compounds, which can be employed to study the phys-
iological function of the GPRC6A receptor in a broader context.
Until now, only two antagonists have been identified for
GPRC6A, the calcimimetic calindol and the calcilytic NPS 2143
(Faure et al., 2009). These suffer from a lack of selectivity as
they were developed to modulate CaR rather than GPRC6A
function and possess 30-fold higher potency on CaR
compared to GPRC6A (Faure et al., 2009). In addition, both
compounds suffer from low solubility and only partial inhibition
of GPRC6A responses are thus obtained at the highest possible
ligand concentrations (Faure et al., 2009), further limiting their
value as pharmacological tools to investigate the GPRC6A
receptor. Strikingly, whereas both ligands inhibit GPRC6A and
bind in overlapping (allosteric) binding sites in the CaR TM1490 Chemistry & Biology 18, 1489–1498, November 23, 2011 ª2011bundle (Miedlich et al., 2004; Petrel et al., 2004), they display
opposite actions at CaR: negative and positive modulation by
NPS 2143 and calindol, respectively. Inherently, it is of essence
to pursue new approaches to ligand identification that are
directed at GPRC6A as the primary target and, preferably, can
adequately define the binding mode and rationale for activity at
this receptor. In the present study, we therefore undertook a
chemogenomic approach to identify a novel GPRC6A antagonist
scaffold.
This study reports two findings of significant novelty. First, it
comprises a pioneering inter-GPCR-family ligand inference,
from Family A to C. The successful extrapolation of ligand scaf-
fold activity is remarkable because of the low sequence
homology between the families and the lack of structural data
for the TM region of Family C GPCRs. Second, we disclose the
identification of the most selective GPRC6A antagonists re-
ported to date, along with an allosteric binding site in the 7TM
region as supported by receptor mutation and ligand substitu-
tion. Selective antagonists constitute important research tools
toward the elucidation of the physiological and therapeutic rele-
vance of GPRC6A.
RESULTS
Chemogenomic Ligand Inference to the GPRC6A Target
The binding modes of three known Family A GPCR privileged
structures; 2-phenyl-indole, 1,10-biaryl-2-acid and 4-aryl-piperi-
dine; have been determined previously, by sequence analysis
and ligand docking, and translated into binding sequence motifs
(Bondensgaard et al., 2004; Garland and Gloriam, 2011b). The
privileged structures are substructures of a large number of
known ligands for Family A GPCRs (Garland and Gloriam,
2011b), but have never been reported to have affinity in other
GPCR families. Here, we matched their binding sequence motifs
to the GPRC6A protein sequence pointing out 2-phenyl-indole
as a candidate ligand scaffold.
Table 1 pairs the 2-phenyl-indole moieties with proposed
interacting GPCR residues. These residues and their physico-
chemical character (aromatic, hydrophobic, charged etc.) con-
stitute the binding sequence motif, which is matched toward
GPRC6A and related receptor protein sequences in Figure 1.
The indole moiety can have aromatic interactions with a hydro-
phobic core site located deep inside the GPCR TM bundle.
Two aromatic residues in positions 5.47, 6.48, 6.51, or 6.52 areElsevier Ltd All rights reserved
Figure 1. The 2-Phenyl-Indole Binding Motif Matched against the Protein Sequences of Assayed Receptors
Protein sequence alignments of TMH3-6 in GPRC6A (human, mouse, and rat), the 5.24 receptor (goldfish), CaR (human and rat), and 5-HT2C (human). The 2-
phenyl-indole binding sequence motif is shown in the top row detailing the residue positions and the moieties they interact with denoted as: indole (I), indole NH
(N), and phenyl (P). Position 3.36 has no specific interaction, but should be uncharged.
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aromatic residues in positions 6.48 and 6.51 (W and F, respec-
tively) and the residues in 5.47 and 6.52 are hydrophobic (A
and I, respectively). The indole nitrogen functionality (NH) is
hypothesized to form a hydrogen bond to the helical backbone
carbonyl of residue position 5.46. Too large (W) or basic (K or
R) side-chains would sterically hinder this interaction, which
is critical for 2-phenyl-indole binding. GPRC6A has an isoleu-
cine in this position and thus matches also this part of the
binding sequence motif. Furthermore, the 2-phenyl moiety
resides in an area enclosed by five residues from TMHs 3, 4,
and 5, of which at least two should be aromatic or hydrophobic.
GPRC6A has two hydrophobic residues (4.56 and 5.46) and
one aromatic residue (4.57). Finally, for the whole structure
to be accommodated, a close strong charge does not seem
to be permitted as it would interfere with its aromatic, hydro-
phobic character. No charge has been observed at any of the
positions 3.36, 3.37, 5.47, 6.51, or 6.52 within known targets or
GPRC6A.
Discovery of 3-Substituted 2-Phenyl-Indoles as Novel
Antagonists at Mouse GPRC6A
We purchased and assayed a selection of 25 compounds
incorporating the 2-phenyl-indole scaffold and a variety of struc-
turally diverse substituents at the indole 3-position (R group in
Table 1). The compounds were initially tested for their ability to
modulate the L-ornithine-induced response at mouse GPRC6A
(mGPRC6A) at EC25 (enhancement) or EC80 (antagonism) of
L-ornithine, using a previously reported inositol phosphate (IP)
turnover assay in tsA201 cells cotransfected with mGPRC6A
and GaqG66D (Christiansen et al., 2007). From this screening,
no allosteric enhancers, and hence no agonists, were identified.
In contrast, nine compounds (36%) displayed antagonistic
effects with IC50 values in the 18–67 mM range (see Table S1
available online).
Selectivity Assessment and Prioritization
of Active Compounds
Active compounds were tested against the rat CaR (closest
mammalian homolog) and the human 5-HT2C receptor (chemo-Chemistry & Biology 18, 1489–149genomically related Family A receptor; see Figure 5). GPRC6A
antagonists 1–3 (Figure 2) were found to be inactive at these
two receptors (Figure 3A; Table S1). In addition, 3 was tested
inactive at the goldfish 5.24 receptor (closest overall homolog
in all species, Figure S1). In order to further evaluate the selec-
tivity of compounds 1–3 they were tested on two additional
Family A (muscarinic acethylcholine receptors M1 and M3) and
Family C (metabotropic glutamate receptors mGlu1 and mGlu5)
GPCRs, which all contain the 2-phenyl-indole binding sequence
motif. 1 and 3 displayed some activity at these receptors,
whereas 2 did not (Table 2). However, all three compounds
displayed at least 3-fold higher potency at GPRC6A than any
of the other tested receptors. All seven receptors screened for
off-target activities contain the 2-phenyl-indole binding
sequence motif (Figure 1). Thus, the selectivity has to be
explained by additional interactions formed by the 3-indole
substituents. The IC50 values of compounds 1–3 are very similar
(18–27 mM) (Figure 3A and Table 2). Compound 2 is the most
selective compound but like 1 suffer from low solubility and
a labile carboxylic ester in the side-chain. Compound 3 is less
selective, but is devoid of the labile carboxylic ester linkage
and has significantly improved aqueous solubility over
compounds 1 and 2 (Table 3). Ligand 1 has better aqueous
solubility than compound 2. Thus, further molecular pharmaco-
logical studies focused on antagonists 1 and 3, representing
both identified ligand classes. To confirm their chemical struc-
tures these were synthesized by us. Both compounds were
spectroscopically identical and displayed IC50 values similar to
the purchased compounds.
Validation of Activity in a Secondary Assay
To confirm the inhibitory activity of the 2-phenyl-indole
compounds at mGPRC6A, 3 was tested in a Xenopus laevis
expression system that is independent on coexpression of
chimeric G proteins and does not risk effects from L-amino acids
in themedia/buffers (Christiansen et al., 2007; Kuang et al., 2005;
Wellendorph et al., 2005). In accordance with the IP assay,
100 mM of compound 3 significantly depressed the L-ornithine-
induced response at a submaximal agonist concentration, but
was devoid of agonist activity (Figure S1).8, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1491
Figure 2. Chemical Structures of Molecules 1–4
Chemical structures of mGPRC6A antagonists 1–3 and an inactive N-methyl
analog 4.
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at mGPRC6A
L-Ornithine concentration-response curves were generated in
the presence of increasing concentrations of 3 (Figure 3B).
This Schild analysis revealed that 3 causes a marked attenuation
of L-ornithine-mediated signaling with no significant effect on
agonist potency, thus, demonstrating that this compound acts
with a noncompetitive mode of action. Similar results were
also obtained for 1 (Figure S2).
Validation of the Binding Mode by Receptor Mutations
The most specific ligand interaction in the binding sequence
motif (Table 1) is the hydrogen bond between the NH of the 2-
phenyl-indole and a carbonyl in the helical backbone of receptor
position 5.46I759. We hypothesized that mutation of this residue;
an isoleucine in mGPRC6A, to a large or basic amino acid would
interfere with bond formation and consequently constructed
tryptophan and arginine mutants. Testing of these mutants in
the IP turnover assay revealed an unchanged responsiveness
to the orthosteric ligand L-ornithine compared to wild-type
mGPRC6A (Table S2). However, in stark contrast the mutated
receptors were not antagonized by 1 or 3 in the presence of
500 mM L-ornithine (Figure 3C; Table S2). These data support
that 1 and 3 critically interact with 5.46I759 in the 7TM domain
of mGPRC6A. This was further corroborated by ligand docking
into a structure model of the mGPRC6A 7TM domain (Figure 4).
Additional Validation of the Binding Mode through
Ligand Substitution
We synthesized an N-methylated analog of compound 1, 4
(Figure 2), which is unable to hydrogen bond to the receptor
backbone due to replacement of the indole NH hydrogen with
a methyl group. As anticipated, analog 4 had no agonistic or
antagonistic activity when tested in the IP turnover assay (Fig-
ure 3D), further substantiating the binding mode.
DISCUSSION
Lead generation by chemogenomic ligand inference has earlier
been demonstrated for the melanin-concentrating hormone1492 Chemistry & Biology 18, 1489–1498, November 23, 2011 ª2011(MCH1), prostanoid DP2 (a.k.a. GPR44/CRTh2), somatostatin 5
(sst5), and anaphylatoxin (C3a) receptors (see Table 1 in Garland
and Gloriam, 2011b). Furthermore, the three privileged struc-
tures studied here, although just a subset of the available, consti-
tute the core scaffolds of more than 100 ligands for 84 GPCR
targets (S. Garland and D.E.G., unpublished data). Remarkably,
hitherto all chemogenomic ligand inferences and privileged
structures apply only to Family A receptors and this report for
GPRC6A, which belongs to Family C, is the first of its kind, to
our knowledge. This represents a breakthrough for the develop-
ment of drugs and pharmacological tool compounds for receptor
families in which structure-based ligand identification/design
and the number of known ligands are still very limited.
The pioneering proof-of-concept for inter-GPCR-family ligand
inference provided in this study is fundamental as it clearly has
achieved what the traditional classifications or similarity
measures, i.e., evolutionary or pharmacological receptor rela-
tionships, cannot (Davies et al., 2011; Garland and Gloriam,
2011a). Specifically, the chemogenomic ligand inference
covered allosteric ligands and crossed GPCR families. The
difference between evolutionary and chemogenomic receptor
relationships is illustrated in Figure 5. The left tree, based on
the whole TM region to represent a conventional evolutionary
phylogenetic analysis, shows a large separation of the Family
C (GPRC6A and CaR, red) and A GPCRs (black). In contrast,
in the right, chemogenomic tree, which is focused on the
2-phenyl-indole binding site, the difference (distance) between
the two families is not bigger than it is between several Family
A members.
Of the 25 compounds, 9 (36%) displayed activity in the 10 mM
range. These results are very satisfactory for an initial ligand
discovery effort, especially when considering that no 2-phenyl-
indole ligands have been reported for any Family C receptors
previously. Additional testing of the active 2-phenyl-indole
compounds revealed that 3 of the 25 compounds are selective
antagonists at the GPRC6A receptor with no activity at CaR or
5-HT2C. Further testing of these three compounds at twomusca-
rinic acetylcholine receptors and two metabotropic glutamate
receptors revealed that all three compound also displayed selec-
tivity for GPRC6A over these receptor subtypes albeit
compound 1 and 3 had some inhibitory activity on some of the
subtypes (Table 2). However, compared to the two only previ-
ously published GPRC6A antagonists, the CaR selective
compounds calindol and NPS 2143, all three compounds show
a superior selectivity profile for GPRC6A.
The GPCR binding sequence motif for the 2-phenyl-indole
suggested that the hydrogen bond interaction between the
indole NH and the 5.46I759 residue in mGPRC6A is essential for
binding. This was supported by the fact that mutations of this
residue to large amino acids, predicted to interfere with the
formation of the hydrogen bond, resulted in lack of effect for
compounds 1 and 3. This was not due to alterations in the
responsiveness of the mGPRC6A receptor, as the mutants re-
sponded similar to the wild-type receptor to the natural ligand
L-ornithine. The confirmed hydrogen bond interaction with the
indole NH together with the observed affinities renders it reason-
able to assume that also the interactions of the indole and phenyl
groups correspond to those in Family A GPCRs (Bondensgaard
et al., 2004). To further substantiate this hypothesis weElsevier Ltd All rights reserved
Figure 3. Pharmacological Characterization of Compounds 1, 3, and 4 on Mouse GPRC6A, Rat CaR and Human 5-HT2A Transiently Ex-
pressed in tsA201 Cells
(A) Concentration-response curves of 3 on the mouse GPRC6A, rat CaR and human 5-HT2C receptors in the presence of 500 mM L-ornithine (L-Orn), 4 mM Ca
2+
and 50 nM serotonin, respectively.
(B) Schild analysis of 3: concentration-response curves of L-Orn in the presence of various concentrations of 3 at the mouse GPRC6A receptor.
(C) Effect of L-Orn and 3 on wild-type and mutated mouse GPRC6A receptors.
(D) Pharmacological characterization of 1 and its N-methylated analog 4 on mouse GPRC6A showing that 1 is an antagonist whereas 4 is inactive. The formation
of inositol phosphates was determined as described in Experimental Procedures. Results are expressed as counts per minute and are means ± SD (n = 3).
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would prevent the hydrogen bond interaction between the
hydrogen of the indole NH and the backbone carbonyl at
5.46I759. As predicted 4 was inactive likely due to lack of this
hydrogen bond. Collectively, the mutations in the receptor andTable 2. Selectivity of Compounds 1–3
Receptor GPRC6A 5-HT2C CaR 5.24
Compound IC50/pIC50 ± SEM/independent experiments (n)
1 27 >100 >100 n.d.
4.58 ± 0.09
9
2 18 >100 >100 n.d.
4.74 ± 0.09
4
3 18 >100 >100 >100
4.75 ± 0.26
5
Antagonist activity of compounds 1–3 at GPRC6A and seven other G prot
motif. All receptors are coupled to the Gq pathway and were tested using
were obtained using Xenopus oocyte electrophysiology. The following s
500 mM L-ornithine (GPRC6A), 50 nM serotonin (5-HT2C), 4 mM Ca
2+ (CaR),
(m3), 60 mM L-glutamate (mGlu1), and 17 mM L-glutamate (mGlu5). n.d., not
Chemistry & Biology 18, 1489–149the N-methyl ‘‘mutation’’ of the compound provide compelling
evidence that the binding site for the 2-phenyl-indole com-
pounds is located in a conserved pocket within the 7TM,
which is further supported by the Schild analysis of the effect
of 1 and 3 on mGPRC6A indicating that the compounds areM1 M3 mGlu1 mGlu5
62 >100 >100 >100
4.22 ± 0.06
4
>100 >100 >100 >100
75 91 >100 56
4.14 ± 0.05 4.06 ± 0.08 4.26 ± 0.05
4 4 3
ein-coupled receptors containing the 2-phenyl indole binding sequence
an inositol phosphate turnover assay except for responses at 5.24 that
ubmaximal (EC80) concentrations of endogenous agonist were used:
30 mM L-ornithine (5.24), 1.6 mM acetylcholine (m1), 86 mM acetylcholine
determined.
8, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1493
Table 3. Potency, Solubility, and Calculated logP of Compounds
1–3
Compound IC50 (mM)
Observed Solubility
in Assay Buffer (mM)
Calculated LogP in
Octanol/Water
(Schro¨dinger QikProp)
1 27 0.2 3.9
2 18 0.1 5.0
3 18 1.0 2.2
Figure 4. Compound 3 Docked in the Mouse GPRC6A Model
Residues are color-coded according to their interacting moiety in the 2-
phenyl-indole binding sequence motif; Green: Indole, Red: Indole NH and
Blue: Phenyl. Residues are indexed using Ballesteros-Weinstein nomenclature
(Ballesteros and Weinstein, 1995).
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more, the inactivity of 1 and 3 on the 5.46I759 mutants and the
lack of activity of 1–3 on some of the other receptor subtypes
tested (Table 2), demonstrate that the antagonists do indeed
act via the GPRC6A receptor and not another receptor ex-
pressed endogenously in the transfected cells.
GPRC6A is one of the most recently deorphanized GPCRs.
This receptor is activated by a range of L-a-amino acids such
as L-arginine, L-lysine and L-ornithine and is positively modu-
lated/activated by the divalent cations Ca2+ andMg2+ (Christian-
sen et al., 2007; Kuang et al., 2005; Pi et al., 2005; Wellendorph
et al., 2005). The omnipresent nature of these ligands in living
beings and their multiple targets severely limit their use as phar-
macological tools for ex vivo and in vivo studies of physiological
functions. We and the groups of Quarles and Karsenty have
therefore generated GPRC6A knockout mice, which, however,
have provided ambiguous results (Pi et al., 2008; Wellendorph
et al., 2009b), presumably due to differences in genetic back-
ground or gene targeting strategy (Conigrave and Hampson,
2010; Wellendorph et al., 2009a). To firmly establish the physio-
logical role of the GPRC6A receptor novel selective pharmaco-
logical tools are thus required. Here, we have presented, to our
knowledge, the first such tools that will be valuable for future
cellular studies. For example, recent studies have reported
putative GPRC6A mediated signaling in cell lines endogenously
expressing the GPRC6A receptor, but used either no controls or
siRNA as control (Oury et al., 2011; Pi et al., 2010; Pi andQuarles,
2011). In our view, the three antagonists reported here would be
of value as additional controls in such studies although potential
inhibition of other GPCRs would have to be considered (Table 2).
The compounds also represent ligands that may be optimized
for higher potency and selectivity to enable ex vivo and in vivo
studies or unlock potential therapeutic effects.
It is well established that the 7TM domain of Family C recep-
tors contains an allosteric binding site, which has previously
been targeted by drug-likemolecules for themetabotropic gluta-
mate, CaR, and GABAB receptors (Bra¨uner-Osborne et al.,
2007). Indeed, the positive allosteric modulator cinacalcet acting
on CaR was the first allosteric GPCR modulator to be marketed
as drug (Jensen and Bra¨uner-Osborne, 2007) and allosteric
modulators for several Family C receptors are actively being
pursued by a number of pharmaceutical companies (Froestl,
2010; Jensen and Bra¨uner-Osborne, 2007; Nicoletti et al.,
2010). The GPRC6A antagonists identified in this study have
overcome the problem that the previously identified GPRC6A
antagonists, calindol and NPS 2143, have with a lack of selec-
tivity. Both compounds were originally designed to modulate
CaR rather than GPRC6A function and are 30 times more
potent at CaR than GPRC6A (Faure et al., 2009). The new1494 Chemistry & Biology 18, 1489–1498, November 23, 2011 ª2011GPRC6A antagonists and calindol both contain an indole;
however, this fragment constitutes a building block in medicinal
chemistry at numerous target families. It is only when the 2-
phenyl is added that the structure adopts a preference for the
GPCR superfamily, and furthermore substitutions at the 3-posi-
tion are required to gain affinity and selectivity (S. Garland
and D.E.G., unpublished data). The current antagonists have
a distinct site of action from calindol, which by mutagenesis
and modeling has been proposed to bind at the top of TM helix
6 and 7 at the extracellular interface (Faure et al., 2009).
Homology models are commonly used tools for structure-
based drug design and lead identification through virtual
screening. However, models of sufficient quality are extremely
difficult to generate for most GPCR families, as templates are
limited to only Family A (six receptors; Cherezov et al., 2007;
Chien et al., 2010; Jaakola et al., 2008; Palczewski et al., 2000;
Scheerer et al., 2008; Warne et al., 2008; Wu et al., 2010)
and interfamily sequence conservation is very low making the
production of reliable alignments challenging. However, in a
few analyses, alignments between GPCR families have been
generated by anchoring TM helices on evolutionarily conserved
residues and validation throughmutagenesis of binding residues
(Binet et al., 2007; Surgand et al., 2006; deGraaf et al., 2011).
There are also several successful examples of how Family C
receptor homology models have been used to predict ligand
binding modes confirmed by mutagenesis (Bra¨uner-Osborne
et al., 2007; Faure et al., 2009). Our Family A–C alignment is vali-
dated by the 2-phenyl-indole activity, which would not be
possible without conservation of the binding site, as well as the
receptor mutation that pinpoints the most crucial ligand interac-
tion. It would be highly warranted to gather the collected support
for inter-GPCR-family alignments that can be used by the scien-
tific community for the building of homologymodels. To that end,Elsevier Ltd All rights reserved
Figure 5. Comparison of Evolutionary and
Chemogenomic Receptor Relationships
A comparison of evolutionary and chemogenomic
receptor relationships based on the full TM region
(left) or the 2-aryl-indole binding site (right). The
trees include 27 Family A GPCRs (black) with
known 2-aryl-indole containing ligands and the
Family C receptors GPRC6A and CaR (red).
Branch lengths indicate receptor (dis)similarities.
The trees were produced with Neighbor of the
Phylip package using the JTT substitution matrix.
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study on the 7TM domain of mGlu5 to test the validity of our
current alignment, which we plan to further substantiate by addi-
tional mutagenesis on GPRC6A. The latter would potentially
further improve our model of the docked antagonists (Figure 4),
and thus provide an important platform for rational design of
novel GPRC6A antagonist analogs with improved potency and
selectivity.
Based on chemogenomic analysis we have identified allo-
steric antagonists for Family C by inference of privileged struc-
tures binding to Family A. Hitherto, this approach had only
been applied within Family A, but our chemogenomic analysis
indicated that the binding sequence motif for 2-phenyl-indoles
was preserved in remotely related Family C receptors including
GPRC6A and this was subsequently confirmed experimentally.
This demonstrates that the use of privileged structures and
receptor binding sequence motifs can be applied in a much
broader context than previously realized. In addition to in silico
ligand inference, chemogenomics may also be used to predict
the identity of unwanted targets; consequently it represents
a new, more rational means for the selection of off-target
screening panels. Moreover, it could also be used to rationalize
polypharmacology and possibly aid the design of drugs display-
ing activity at a profile of (chemogenomically) similar targets.
Most chemogenomic analyses have been performed on GPCR
targets, but there are also substantial data for protein kinasesChemistry & Biology 18, 1489–1498, November 23, 2011 ª(Harris and Stevens, 2006; Vieth et al.,
2004) and even interprotein family com-
parisons based on crystal structures
(Weill and Rognan, 2010). It can therefore
be anticipated that chemogenomic tech-
niques will gain a wide implementation
as more structural ligand binding mode
data are deposited.
SIGNIFICANCE
GPCRs form one of the largest pro-
tein families in human (Venter et al.,
2001) and are the targets of 27%–45%
of marketed drugs (Drews, 2000; Hop-
kins and Groom, 2002; Overington
et al., 2006). This study presents, to
our knowledge, the first ever ligand
inference across GPCR families. This
is remarkable because of the lowsequence homology between the families and the lack of
structural data for other than the Family A class. This
proof-of-concept for in silico approaches against Family C
targets based on Family A templates greatly expands the
prospects of drug design and discovery. Specifically, it
facilitates alignment and receptor 3D homology model
building as well as potential inference of further ligands
binding in the TM domain. This domain encompasses most
of the many Family A ligands, but is an allosteric binding
site for Family C receptors that instead are physiologically
activated by binding in a large amino-terminal ‘‘Venus-
flytrap’’ domain. Allosteric ligands have a range of advan-
tages including the possibility to gain increased selectivity,
fine-tune an endogenous response or generating function-
ally selective responses. GPRC6A was recently discovered
and deorphanized by our group (Christiansen et al., 2007;
Kuang et al., 2005; Pi et al., 2005; Wellendorph and Bra¨u-
ner-Osborne, 2004; Wellendorph et al., 2005). The antago-
nists 1–3 constitute novel research tools for investigating
the signaling mechanism of the GPRC6A receptor at the
cellular level. They also constitute lead structures for further
optimization of potency and selectivity, which would enable
elucidation of the wider physiological function and thera-
peutic relevance of GPRC6A, a receptor already linked to
severe metabolic and endocrinological disturbances (Oury
et al., 2011; Pi et al., 2008; Wellendorph et al., 2009b).2011 Elsevier Ltd All rights reserved 1495
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Alignment of the Transmembrane Helices of Family A and C GPCRs
MEGA version 4.0 was used to produce ungapped protein sequence align-
ments of the seven TM helices of the majority of the human Family A and all
Family C receptors, respectively. Subsequently, a Family A to C alignment
was made anchoring the TM helices on residues conserved in a large number
of receptor homologs and orthologs (Bjarnado´ttir et al., 2006; Gloriam et al.,
2007; Haitina et al., 2009; Lagerstro¨m et al., 2006). TMH3 was anchored on
C3.26 that forms a conserved disulphide bond to ECL2. THM4 was aligned
based on P4.60, which is conserved in the glutamate receptors, TAS1R,
GPRC6A, and CaR. TMH5 was fit to give the best overall alignment using
the alignment program MUSCLE inside MEGA being placed in between the
disulphide bonding cysteine residue in ECL2 and TMH6. These structural
elements are close and restrict the alignment of TMH5 in Family C receptors.
In GPRC6A, they are separated by only 3 residues on each side. THM6 was
anchored on W6.48.
Chemogenomic Binding Motif-Based Ligand Inference
We utilized a chemogenomic approach to assess whether the privileged struc-
tures 2-acid-1,10-biphenyl, 2-phenyl-indole or basic 4-aryl-piperidine, which
are substructures of a large number of Family A GPCRs ligands (Bondens-
gaard et al., 2004), were also likely to bind in GPRC6A. The binding modes
of the three privileged structures had previously been determined by docking
and mutagenesis and are conserved among targets (Bondensgaard et al.,
2004; Garland and Gloriam, 2011b). For each privileged structure, a binding
sequence motif defined: (1) which positions (sites) in the sequence alignment
that interact with the ligand and (2) which of the natural amino acids that can
mediate the given ligand interaction at each positions. The positions were in-
dexed using Ballesteros-Weinstein indexing (Ballesteros and Weinstein, 1995)
and amino acid flavors as simple sets, for example F, W, Y, or H for aromatic
interactions. The binding sequence motifs were matched against the aligned
GPRC6A protein sequence. Twenty-five compounds were purchased that
contain the 2-phenyl-indole scaffold (only matching binding motif) with struc-
turally diverse substituents on the indole 3-position.
GPRC6A modeling and ligand docking
A homology model of mouse GPRC6A was constructed with MODELER
version 9v6. The high-resolution human b2-adrenergic crystal structure
(Cherezov et al., 2007) was retrieved from PDB (PDB ID: 2RH1) and used as
template. Five hundred models were constructed using the default settings
and the model with the best DOPE score was chosen. Compound 3 was
manually docked in the mGPRC6A model using Maestro (Schro¨dinger LCC).
Culturing and Transfection of tsA201 and CHO cells
tsA201 cells (Chahine et al., 1994) were cultured in GlutaMAX-I DMEM
medium, supplemented with 10% dialyzed fetal bovine serum and penicillin
(100 U/ml)/streptomycin (100 mg/ml) at 37C in a humidified atmosphere of
5% ambient CO2. Cells were transfected using PolyFect (QIAGEN, West
Sussex, UK) with mouse GPRC6A, human 5-HT2C, rat CaR, goldfish 5.24,
and human M1 or human M3 plasmid DNA as previously described (Bonner
et al., 1987; Christiansen et al., 2006, 2007). To enable efficient coupling of
mGPRC6A and mutant receptors to phospholipase C, the receptors were
coexpressed with GaqG66D (1:1 transfection ratio) (Christiansen et al., 2007;
Heydorn et al., 2004). For the IP turnover assay, transfected cells were
split into poly-D-lysine coated 96-well plates the day before assaying and
grown to confluence in inositol-free DMEM medium supplemented with
antibiotics, serum and 0.15 MBq/ml myo-[2-3H]inositol (GE Healthcare,
Buckinghamshire, UK).
CHO cells stably expressing the rat mGlu1 or mGlu5 receptors were cultured
in GlutaMAX-I DMEM medium, supplemented with 10% dialyzed fetal bovine
serum, 1% L-proline and penicillin (100 U/ml)/streptomycin (100 mg/ml) at
37C in a humidified atmosphere of 5% ambient CO2 as previously described
(Hermit et al., 2004).
IP Turnover Assay
The assay on transfected tsA was carried out as previously described
(Christiansen et al., 2007; Wellendorph et al., 2005). In brief, the cells were1496 Chemistry & Biology 18, 1489–1498, November 23, 2011 ª2011prewashed for 2 3 2 hr at 37C with buffer containing Hank’s balanced salt
Solution (HBSS) containing 20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, and
1 mg/ml BSA [pH 7.4]) (Kuang et al., 2005). The cells were washed and
preincubated with buffer or allosteric modulator in 50 ml assay buffer (HBSS
containing 20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, and 20 mM LiCl [pH
7.4]) for 30 min at 37C. Following this preincubation, the cells were stimulated
with 50 ml of agonist with or without modulator in assay buffer for 30 min at
37C. The reactions were stopped by exchanging the buffer with 50 ml
10 mM ice-cold formic acid and incubating the cells at 4C for at least
30 min. Yttrium silicate scintillation proximity assay beads (PerkinElmer,
Waltham, CA, USA) were used for measuring radioactivity from generated
[3H]IP, as previously described (Brandish et al., 2003; Christiansen et al.,
2007). Radioactivity was quantified in a Packard TopCount microplate
scintillation counter and responses read as counts per minute. All data
points were performed in triplicate and experiments performed in at least
three independent repetitions. The IP turnover assay on CHO cells was
performed as previously described (Hermit et al., 2004), which is the same
protocol as detailed above, except from omission of the 2 3 2 hr prewashing
step.
Electrophysiology
Preparation of oocytes from Xenopus laevis frogs and injection with in vitro-
transcribed cRNA encoding mGPRC6A were carried out as described
previously (Wellendorph et al., 2005). In brief, mGPRC6A in pGEMHE-3Z
was linearized with SapI, transcribed to cRNAs with mMessage mMachine
kits (Ambion, Austin, TX, USA) and cRNA injected into harvested healthy-look-
ing stage V–VI oocytes. Whole cell currents were recorded from oocytes
4–5 days after injection using two-electrode voltage clamp at 60 mV in
ND96 solution (in mM): NaCl (96), KCl (2), MgCl2 (1), CaCl2 (1.8), HEPES
(hemi-Na salt; 5) supplemented with sodium pyruvate (2.5), theophylline (0.5)
and 50 mg/ml gentamycin (pH 7.4). Recordings were performed at room
temperature by means of a Geneclamp 500 amplifier (Axon Instruments,
Foster City, CA, USA), a MacLab 2e recorder (AD Instruments, Sydney,
NSW) and LabChart (AD Instruments). Oocytes were voltage-clamped at
60 mV using glass microelectrodes filled with 3 mM KCl (0.5–1.5 MU). The
preparation was continually perfused with ND96 solution. The ligands were
dissolved in ND96 and applied to the oocytes by gravity-driven perfusion.
Currents were digitized at 100 Hz.
Construction of mGPRC6A Mutants
Single amino acid replacement was carried out by the QuikChange method
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s instructions.
The identity of eachmutant was confirmed byDNA sequencing (EurofinsMWG
Operon, Ebersberg, Germany).
Compound Synthesis
To supply sufficient amounts of ligands 1 and 3 and to confirm their chemical
structures they were synthesized in-house. Both compounds, as well as
the N-methylated analog 4, were synthesized from commercially available
2-phenyl-indole using a Friedel-Craft acylation approach. All spectral data
for ligands 1 and 3 were identical to that for the commercially available
compounds, confirming their identities. (full details are available in the Supple-
mental Experimental Procedures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, two figures, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
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